Indiplon-IR PDUFA delayed

Neurocrine (NBIX) said FDA refused to file its NDA for indiplon immediate-release capsules to treat insomnia because of technical problems with the electronic application. As a result, NBIX said the

Read the full 307 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE